Anti-CD20 monoclonal antibody that depletes B cells via ADCC, CDC, and apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes CD20-positive malignant and normal B cells via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and induction of apoptosis.
Binding to CD20 triggers Fc-mediated ADCC by NK cells/macrophages, complement-dependent cytotoxicity (CDC), and can directly induce apoptosis via CD20 crosslinking.
Anti-CD79b antibody–drug conjugate delivering MMAE to B cells, causing microtubule disruption and cell death.
Anti-CD79b monoclonal antibody–drug conjugate that binds CD79b on B cells, is internalized, and releases the microtubule inhibitor MMAE after linker cleavage, causing tubulin polymerization blockade, G2/M arrest, and apoptosis of malignant B cells.
Anti-CD79b ADC binds CD79b on B cells, is internalized, linker is cleaved, releasing MMAE that inhibits tubulin polymerization, causing G2/M arrest and apoptosis of the target cell.
Oral tyrosine kinase inhibitor active against NTRK1/2/3, ROS1, and ALK fusion kinases.
Oral tyrosine kinase inhibitor that selectively targets TRKA/B/C (NTRK1/2/3), ROS1, and ALK fusion kinases, blocking their signaling (e.g., MAPK and PI3K pathways) to inhibit tumor proliferation and induce apoptosis in fusion-positive cancers.
Entrectinib directly inhibits TRKA (NTRK1) kinase activity in TRKA-driven tumor cells, blocking MAPK/PI3K signaling and inducing growth arrest and apoptosis.
Oral tyrosine kinase inhibitor active against NTRK1/2/3, ROS1, and ALK fusion kinases.
Oral tyrosine kinase inhibitor that selectively targets TRKA/B/C (NTRK1/2/3), ROS1, and ALK fusion kinases, blocking their signaling (e.g., MAPK and PI3K pathways) to inhibit tumor proliferation and induce apoptosis in fusion-positive cancers.
Entrectinib is a small‑molecule TKI that inhibits TRKB (NTRK2) kinase activity, blocking downstream MAPK/PI3K survival signaling and inducing apoptosis of TRKB‑driven tumor cells (e.g., NTRK fusions).
Oral tyrosine kinase inhibitor active against NTRK1/2/3, ROS1, and ALK fusion kinases.
Oral tyrosine kinase inhibitor that selectively targets TRKA/B/C (NTRK1/2/3), ROS1, and ALK fusion kinases, blocking their signaling (e.g., MAPK and PI3K pathways) to inhibit tumor proliferation and induce apoptosis in fusion-positive cancers.
Entrectinib directly inhibits TRKC (NTRK3) kinase activity, shutting down MAPK/PI3K survival signaling in TRKC-driven tumor cells and inducing apoptosis.